NewAmsterdam Pharma Files 8-K Report

TL;DR

NAMP filed an 8-K with financial statements and exhibits on June 11, 2024.

AI Summary

On June 11, 2024, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that NewAmsterdam Pharma is providing updated financial statements and exhibits, which is a standard disclosure requirement for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report containing financial statements and exhibits, with no immediate indication of significant new risks or material adverse events.

Key Players & Entities

• NewAmsterdam Pharma Company N.V. (company) — Registrant
• June 11, 2024 (date) — Date of earliest event reported
• 001-41562 (company) — Commission File Number

FAQ

Filing Documents

• d851893d8k.htm (8-K) — 33KB
• d851893dex991.htm (EX-99.1) — 13KB
• 0001193125-24-158751.txt ( ) — 211KB
• nams-20240611.xsd (EX-101.SCH) — 3KB
• nams-20240611_def.xml (EX-101.DEF) — 14KB
• nams-20240611_lab.xml (EX-101.LAB) — 23KB
• nams-20240611_pre.xml (EX-101.PRE) — 15KB
• d851893d8k_htm.xml (XML) — 6KB

Forward-Looking Statements

Forward-Looking Statements Certain statements included in this Item 8.01 that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company's intellectual property and its ability to enforce, and sufficiency of, its patents, business and strategic plans, the Company's commercial opportunity, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company's product candidate and the timing of expected regulatory and business milestones, including potential commercialization; ability to negotiate definitive contractual arrangements with potential custome

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Press Release, dated June 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: June 11, 2024

View Full Filing

View this 8-K filing on SEC EDGAR